Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI

被引:26
|
作者
Takasu, Miyuki [1 ]
Kondo, Shota [1 ]
Akiyama, Yuji [1 ]
Takahashi, Yuji [1 ]
Maeda, Shogo [1 ]
Baba, Yasutaka [1 ]
Kawase, Takakazu [2 ]
Ichinohe, Tatsuo [2 ]
Awai, Kazuo [1 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Diagnost Radiol, Hiroshima, Japan
[2] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; BONE-MARROW; DIAGNOSTIC PERFORMANCE; F-18-FDG PET/CT; IMAGING PATTERN; SURVIVAL; DIFFERENTIATION; BIOMARKER; CRITERIA;
D O I
10.1371/journal.pone.0229607
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives To compare remission status at completion of chemotherapy for multiple myeloma (MM) with changes in total diffusion volume (tDV) calculated from whole-body diffusion-weighted imaging (WB-DWI) and fat fraction (FF) of lumbar bone marrow (BM) by modified Dixon Quant (mDixon Quant) soon after induction of chemotherapy, and to assess the predictive value of MRI. Methods Fifty patients (mean age, 66.9 +/- 10.5 years) with symptomatic myeloma were examined before and after two cycles of chemotherapy. From WB-DWI data, tDV was obtained with the threshold for positive BM involvement. Mean FF was calculated from lumbar BM using the mDixon Quant sequence. At the completion of chemotherapy, patients were categorized into a CR/very good PR (VGPR) group (n = 15; mean age, 67.6 +/- 10.3 years) and a PR, SD or PD group (n = 35; mean age, 69.1 +/- 8.6 years). ROC curves were plotted to assess performance in predicting achievement of CR/VGPR. Results At second examination, serum M protein, beta(2)-microglobulin, and tDV were significantly decreased and hemoglobin, mean ADC, and FF were significantly increased in the CR/VGPR group and serum M protein was significantly increased in the PR/SD/PD group. The general linear model demonstrated that percentage changes in FF and M protein contributed significantly to achieving CR/VGPR (P = 0.02, P = 0.04, respectively). AUCs of ROC curves were 0.964 for FF and 0.847 for M protein. Conclusions Early change in FF of lumbar BM and serum M protein soon after induction of chemotherapy contributed significantly to prediction of CR/VGPR.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma
    Lacognata, C.
    Crimi, F.
    Guolo, A.
    Varin, C.
    De March, E.
    Vio, S.
    Ponzoni, A.
    Barila, G.
    Lico, A.
    Branca, A.
    De Biasi, E.
    Gherlinzoni, F.
    Scapin, V.
    Bissoli, E.
    Berno, T.
    Zambello, R.
    CLINICAL RADIOLOGY, 2017, 72 (10) : 850 - 857
  • [2] Whole-Body Diffusion-Weighted MRI With Apparent Diffusion Coefficient Mapping for Early Response Monitoring in Multiple Myeloma: Preliminary Results
    Horger, Marius
    Weisel, Katja
    Horger, Wilhelm
    Mroue, Ali
    Fenchel, Michael
    Lichy, Matthias
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 196 (06) : W790 - W795
  • [3] Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma
    Zambello, Renato
    Barila, Gregorio
    Crimi, Filippo
    Annamaria, Guolo
    Vio, Stefania
    Ponzoni, Alberto
    Lico, Albana
    Branca, Antonio
    Berno, Tamara
    De March, Elena
    Ammirati, Lucia
    Leoncin, Matteo
    De Biasi, Ercole
    Semenzato, Gianpietro
    Lacognata, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E118 - E118
  • [4] Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma
    Dutoit, Julie C.
    Verstraete, Koenraad L.
    SKELETAL RADIOLOGY, 2017, 46 (06) : 733 - 750
  • [5] Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma
    Julie C. Dutoit
    Koenraad L. Verstraete
    Skeletal Radiology, 2017, 46 : 733 - 750
  • [6] Whole-Body Diffusion-weighted MR Imaging for Assessment of Treatment Response in Myeloma
    Giles, Sharon L.
    Messiou, Christina
    Collins, David J.
    Morgan, Veronica A.
    Simpkin, Catherine J.
    West, Sharon
    Davies, Faith E.
    Morgan, Gareth J.
    deSouza, Nandita M.
    RADIOLOGY, 2014, 271 (03) : 785 - 794
  • [7] Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI
    Theruvath, Ashok J.
    Siedek, Florian
    Muehe, Anne M.
    Garcia-Diaz, Jordi
    Kirchner, Julian
    Martin, Ole
    Link, Michael P.
    Spunt, Sheri
    Pribnow, Allison
    Rosenberg, Jarrett
    Herrmann, Ken
    Gatidis, Sergios
    Schafer, Jurgen F.
    Moseley, Michael
    Umutlu, Lale
    Daldrup-Link, Heike E.
    RADIOLOGY, 2020, 296 (01) : 143 - 151
  • [8] Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma
    Charles Mesguich
    Cyrille Hulin
    Valerie Latrabe
    Axelle Lascaux
    Laurence Bordenave
    Elif Hindié
    Gerald Marit
    Annals of Hematology, 2020, 99 : 2869 - 2880
  • [9] Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma
    Mesguich, Charles
    Hulin, Cyrille
    Latrabe, Valerie
    Lascaux, Axelle
    Bordenave, Laurence
    Hindie, Elif
    Marit, Gerald
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2869 - 2880
  • [10] Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging
    van den Berghe, Thomas
    Verberckmoes, Bert
    Kint, Nicolas
    Wallaert, Steven
    De Vos, Nicolas
    Algoet, Chloe
    Behaeghe, Maxim
    Dutoit, Julie
    Van Roy, Nadine
    Vlummens, Philip
    Dendooven, Amelie
    Van Dorpe, Jo
    Offner, Fritz
    Verstraete, Koenraad
    INSIGHTS INTO IMAGING, 2024, 15 (01)